Evolution  	Evolution  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
antibiotic  	antibiotic  	 JJ	B-NP
susceptibility  	susceptibility  	 NN	I-NP
and  	and  	 CC	O
resistance  	resistance  	 NN	O
Over  	Over  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
decade  	decade  	 NN	O
the  	the  	 DT	O
proliferation  	proliferation  	 NN	B-NP
of  	of  	 IN	O
antibiotic-resistant  	antibiotic-resistant  	 JJ	O
pathogens  	pathogens  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
a  	a  	 DT	O
growing  	growing  	 VBG	B-NP
problem 	problem 	 NN	I-NP
,  	,  	 ,	O
especially  	especially  	 RB	O
in  	in  	 IN	O
some  	some  	 DT	O
geographic  	geographic  	 JJ	B-NP
areas 	areas 	 NNS	I-NP
,  	,  	 ,	O
making  	making  	 VBG	O
useless  	useless  	 JJ	O
most  	most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
classical  	classical  	 JJ	B-NP
antibiotic  	antibiotic  	 JJ	I-NP
therapies 	therapies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
rapid  	rapid  	 JJ	B-NP
emergence  	emergence  	 NN	I-NP
of  	of  	 IN	O
resistant  	resistant  	 JJ	O
bacteria  	bacteria  	 NNS	O
is  	is  	 VBZ	O
the  	the  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
different  	different  	 JJ	O
factors  	factors  	 NNS	O
as  	as  	 IN	O
the  	the  	 DT	O
intrinsic  	intrinsic  	 JJ	B-NP
microbial  	microbial  	 JJ	I-NP
complexity 	complexity 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
growing  	growing  	 VBG	B-NP
attitude  	attitude  	 NN	I-NP
to  	to  	 TO	O
travel  	travel  	 VB	O
of  	of  	 IN	O
humans 	humans 	 NNS	O
,  	,  	 ,	O
animals  	animals  	 NNS	O
and  	and  	 CC	O
goods 	goods 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
antibiotics  	antibiotics  	 JJ	O
outside  	outside  	 JJ	O
hospitals 	hospitals 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
precise  	precise  	 JJ	O
therapeutic  	therapeutic  	 NN	O
chooses  	chooses  	 VBZ	O
for  	for  	 IN	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
group  	group  	 NN	I-NP
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
antibiotic-resistance  	antibiotic-resistance  	 NN	B-NP
becomes  	becomes  	 VBZ	O
certainly  	certainly  	 RB	O
a  	a  	 DT	O
serious  	serious  	 JJ	B-NP
problem  	problem  	 NN	I-NP
when  	when  	 WRB	O
a  	a  	 DT	O
resistant  	resistant  	 JJ	O
pathogen 	pathogen 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
often  	often  	 RB	O
multi-resistant  	multi-resistant  	 JJ	B-NP
today 	today 	 NN	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
present  	present  	 JJ	O
in  	in  	 IN	O
an  	an  	 DT	O
infective  	infective  	 JJ	B-NP
site 	site 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
fact  	fact  	 NN	O
in  	in  	 IN	O
a  	a  	 DT	O
recent  	recent  	 JJ	O
estimate  	estimate  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Centre  	Centre  	 NNP	O
for  	for  	 IN	O
Disease  	Disease  	 NNP	B-NP
Control  	Control  	 NNP	I-NP
and  	and  	 CC	O
Prevention  	Prevention  	 NNP	O
( 	( 	 -LRB-	O
CDC 	CDC 	 NNP	B-NP
)  	)  	 -RRB-	O
about  	about  	 IN	O
90.000  	90.000  	 CD	O
deaths  	deaths  	 NNS	O
per  	per  	 IN	O
year  	year  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
USA  	USA  	 NNP	B-NP
are  	are  	 VBP	O
attributable  	attributable  	 JJ	O
to  	to  	 TO	O
bacterial  	bacterial  	 JJ	B-NP
infections  	infections  	 NNS	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
particular  	particular  	 JJ	O
to  	to  	 TO	O
resistant  	resistant  	 JJ	O
pathogens 	pathogens 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
appears  	appears  	 VBZ	O
clear  	clear  	 JJ	O
that  	that  	 IN	O
the  	the  	 DT	O
clinic  	clinic  	 NN	O
relevance  	relevance  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
problem  	problem  	 NN	O
is  	is  	 VBZ	O
the  	the  	 DT	O
decimation  	decimation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
sensible  	sensible  	 JJ	O
germs  	germs  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
normal  	normal  	 JJ	B-NP
flora  	flora  	 NNS	I-NP
that  	that  	 WDT	O
leads  	leads  	 VBZ	O
to  	to  	 TO	O
the  	the  	 DT	O
upper  	upper  	 JJ	O
hand  	hand  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
only  	only  	 JJ	O
resistant  	resistant  	 JJ	O
bacteria 	bacteria 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
antibiotic  	antibiotic  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
fact 	fact 	 NN	O
,  	,  	 ,	O
select  	select  	 VB	O
the  	the  	 DT	O
resistance  	resistance  	 NN	O
and  	and  	 CC	O
each  	each  	 DT	O
bacteria  	bacteria  	 NN	O
has  	has  	 VBZ	O
developed  	developed  	 VBN	O
a  	a  	 DT	O
particular  	particular  	 JJ	O
strategy  	strategy  	 NN	O
to  	to  	 TO	O
survive 	survive 	 VB	O
:  	:  	 :	O
mutations  	mutations  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
genetic  	genetic  	 JJ	B-NP
content  	content  	 NN	I-NP
or  	or  	 CC	O
acquisition  	acquisition  	 NN	O
of  	of  	 IN	O
resistance  	resistance  	 NN	B-NP
genes  	genes  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
external 	external 	 JJ	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
Gram  	Gram  	 JJ	O
positive  	positive  	 JJ	B-NP
bacteria 	bacteria 	 NNS	I-NP
,  	,  	 ,	O
besides  	besides  	 FW	O
methicillin  	methicillin  	 FW	B-NP
resistant  	resistant  	 FW	O
Staphyloccocus  	Staphyloccocus  	 FW	B-NP
aureus 	aureus 	 FW	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
are  	are  	 VBP	O
other  	other  	 JJ	O
pathogens  	pathogens  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
coagulase-negative  	coagulase-negative  	 JJ	B-NP
staphylococci  	staphylococci  	 NNS	I-NP
( 	( 	 -LRB-	O
CoNS 	CoNS 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Enterococcus  	Enterococcus  	 NNP	B-NP
faecium  	faecium  	 NN	I-NP
and  	and  	 CC	O
Enterococcus  	Enterococcus  	 NNP	B-NP
faecalis 	faecalis 	 NN	I-NP
,  	,  	 ,	O
some  	some  	 DT	O
species  	species  	 NN	B-NP
of  	of  	 IN	O
streptococci  	streptococci  	 NN	O
and  	and  	 CC	O
multiresistant  	multiresistant  	 JJ	B-NP
Corynebacterium 	Corynebacterium 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
CoNS 	CoNS 	 JJ	O
,  	,  	 ,	O
eg 	eg 	 NN	B-NP
.  	.  	 .	O
S.  	S.  	 NNP	B-NP
epidermidis 	epidermidis 	 NN	I-NP
,  	,  	 ,	O
S.  	S.  	 NNP	B-NP
hominis  	hominis  	 NN	I-NP
and  	and  	 CC	O
S.  	S.  	 NNP	B-NP
haemolyticus 	haemolyticus 	 NN	I-NP
,  	,  	 ,	O
are  	are  	 VBP	O
recognized  	recognized  	 VBN	O
as  	as  	 IN	O
new  	new  	 JJ	O
important  	important  	 JJ	O
nosocomial  	nosocomial  	 JJ	B-NP
pathogens  	pathogens  	 NN	I-NP
and  	and  	 CC	O
are  	are  	 VBP	O
not  	not  	 RB	O
only  	only  	 RB	O
responsible  	responsible  	 JJ	O
of  	of  	 IN	O
invasive  	invasive  	 JJ	B-NP
infections  	infections  	 NNS	I-NP
but  	but  	 CC	O
have  	have  	 VBP	O
become  	become  	 VBN	O
in  	in  	 IN	O
few  	few  	 JJ	O
years  	years  	 NNS	O
resistant  	resistant  	 VBP	O
to  	to  	 TO	O
oxacillin  	oxacillin  	 VB	O
( 	( 	 -LRB-	O
more  	more  	 JJR	O
than  	than  	 IN	O
60 	60 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
multiresistant 	multiresistant 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
unsuspected  	unsuspected  	 JJ	O
fragility  	fragility  	 NN	O
of  	of  	 IN	O
glycopeptides 	glycopeptides 	 NN	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
for  	for  	 IN	O
40  	40  	 CD	O
years  	years  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
the  	the  	 DT	O
most  	most  	 RBS	O
important  	important  	 JJ	O
treatment  	treatment  	 NN	O
against  	against  	 IN	O
infections  	infections  	 JJ	O
due  	due  	 JJ	O
to  	to  	 TO	O
Gram-positive  	Gram-positive  	 JJ	B-NP
bacteria 	bacteria 	 NNS	I-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
posed  	posed  	 VBN	O
the  	the  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
new  	new  	 JJ	O
antimicrobial  	antimicrobial  	 JJ	B-NP
molecules 	molecules 	 NNS	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
possible  	possible  	 JJ	I-NP
options  	options  	 NNS	I-NP
there  	there  	 EX	O
are  	are  	 VBP	O
linezolid 	linezolid 	 VBN	O
,  	,  	 ,	O
tygecyline  	tygecyline  	 NN	B-NP
and  	and  	 CC	O
daptomycin 	daptomycin 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
new  	new  	 JJ	O
other  	other  	 JJ	O
molecules  	molecules  	 NNS	O
are  	are  	 VBP	O
appearing  	appearing  	 VBG	O
in  	in  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
use  	use  	 NN	I-NP
like  	like  	 IN	O
ceftobiprole  	ceftobiprole  	 NN	B-NP
and  	and  	 CC	O
dalbavancin 	dalbavancin 	 NN	B-NP
.  	.  	 .	O
